Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
@article{Home2009RosiglitazoneEF, title={Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial}, author={Philip D. Home and Stuart J. Pocock and Henning Beck-Nielsen and Paula Curtis and Ramon Gomis and Markolf Hanefeld and Nigel P. Jones and Michel Komajda and John J. V. McMurray}, journal={The Lancet}, year={2009}, volume={373}, pages={2125-2135} }
1,308 Citations
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
- MedicineThe lancet. Diabetes & endocrinology
- 2017
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
- MedicineEuropean heart journal
- 2010
Findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication.
Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
- MedicineScientific reports
- 2021
Combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
- MedicineCardiovascular diabetology
- 2011
In patients with T2D failing prior hypoglycemic therapies, Pio combinations with SU or Met (especially Pio + Met) improved blood lipid and glycemic profiles, decreasing the proportion of patients with a high microvascular or macrovascular risk.
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
- MedicineDiabetologia
- 2010
The malignancies rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone, but they do not refute the possibility of a difference compared with sulfonylureas.
Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Medicine, BiologyScientific Reports
- 2019
Meta-analysis supported pioglitazone as an effective treatment option for T2DM patients to ameliorate hyperglycaemia, adverse lipid metabolism and blood pressure.
Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- MedicinemedRxiv
- 2020
A combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative to combination Therapy of met formin and sulphonylureas for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
- MedicineCurrent medical research and opinion
- 2011
Compared to rosiglitazone 4āmg plus glimepiride, liraglutide is a cost-effective treatment option for improving glucose control in T2DM, particularly at the 1.2-mg dose.
Database Evaluation of the Effects of LongāTerm Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
- MedicineJournal of clinical pharmacology
- 2011
In this communityābased cohort, 30 months of therapy with rosiglitazone treatment was associated with increased risk of CHF but was not associated withincreased risk of AMI, ACS, coronary revascularization, or allācause mortality.
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
- MedicineAnnales d'endocrinologie
- 2010
References
SHOWING 1-10 OF 23 REFERENCES
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
- MedicineCardiovascular diabetology
- 2008
Changes in BP were not accompanied by compensatory increases in heart rate, did not correlate with basal insulin sensitivity estimates and were not explained by changes in antihypertensive therapy between the various strata.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
- MedicineDiabetologia
- 2005
The RECORD study should provide robust data on the extent to which rosiglitazone, in combination with metformin or sulphonylurea therapy, affects CV outcomes and progression of diabetes in the long term.
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
- MedicineThe New England journal of medicine
- 2007
The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
- MedicineThe New England journal of medicine
- 2006
The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
- Medicine
- 1998
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
- MedicineThe Lancet
- 2005
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- MedicineThe Lancet
- 1998
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
- MedicineThe New England journal of medicine
- 2007
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
10-year follow-up of intensive glucose control in type 2 diabetes.
- MedicineThe New England journal of medicine
- 2008
Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
- MedicineJAMA
- 2007
Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantlyIncreased risk of cardiovascular mortality.